Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | PNLIP | P16233 | 1/20 | 0.64 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | FADS1 | O60427 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PTPRC | P08575 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811784 | 0.92 | KMT2A (0.63) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL27315886 | 0.87 | KMT2A (0.64) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL6819360 | 0.87 | FADS1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL4254011 | 0.85 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL6811790 | 0.85 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL6816284 | 0.84 | MAPT (0.62) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL4242085 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL13878279 | 0.83 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL6815397 | 0.83 | FADS1 (0.66) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL10489740 | 0.83 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.